[AQXP] Aquinox Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 16.61 Change: 1.5 (9.93%)
Ext. hours: Change: 0 (0%)

chart AQXP

Refresh chart

Strongest Trends Summary For AQXP

AQXP is in the long-term down -89% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aquinox Pharmaceuticals Inc., a clinical stage pharmaceutical company, discovers and develops oral drug candidates for the treatment of inflammatory diseases and cancer. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its principal product candidate is AQX-1125, a SHIP1 activator, which is in Phase II clinical trials for chronic obstructive pulmonary disease and bladder pain syndrome/interstitial cystitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.93 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-6.93
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-74.61% ROE-87.13% ROI
Current Ratio7.04 Quick Ratio Long Term Debt/Equity Debt Ratio0.17
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities6.06 M Cash From Operating Activities-6.75 M Gross Profit
Net Profit-6.41 M Operating Profit-6.04 M Total Assets35.13 M Total Current Assets35.02 M
Total Current Liabilities4.97 M Total Debt Total Liabilities5.05 M Total Revenue
Technical Data
High 52 week15.72 Low 52 week2.07 Last close2.68 Last change-1.11%
RSI47.78 Average true range0.09 Beta0.88 Volume125.46 K
Simple moving average 20 days-0.95% Simple moving average 50 days-0.13% Simple moving average 200 days2.76%
Performance Data
Performance Week-3.25% Performance Month3.88% Performance Quart0% Performance Half19.64%
Performance Year-78.7% Performance Year-to-date24.07% Volatility daily1.53% Volatility weekly3.43%
Volatility monthly7.03% Volatility yearly24.35% Relative Volume208.01% Average Volume67.93 K
New High New Low

News

2019-08-09 08:00:00 | Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction

2019-08-08 02:02:57 | UW spinout Neoleukin Therapeutics goes public in acquisition

2019-08-07 08:00:00 | Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

2019-08-06 07:00:00 | Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement

2019-07-26 14:24:45 | Imagine Owning Aquinox Pharmaceuticals NASDAQ:AQXP While The Price Tanked 68%

2019-04-26 15:49:43 | What Kind Of Shareholder Appears On The Aquinox Pharmaceuticals, Inc.'s NASDAQ:AQXP Shareholder Register?

2018-11-07 10:21:40 | Aquinox: 3Q Earnings Snapshot

2018-11-07 09:15:00 | Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results

2018-11-01 08:55:00 | Consolidated Research: 2018 Summary Expectations for Aquinox Pharmaceuticals, Xilinx, West Pharmaceutical Services, nVent Electric, World Wrestling Entertainment, and HD Supply — Fundamental Analysis, Key Performance Indications

2018-08-08 06:22:35 | Aquinox: 2Q Earnings Snapshot

2018-08-08 06:15:00 | Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

2018-07-24 09:00:00 | These Small Biotech Companies Could Bring a 300% Return Before end of the Year

2018-07-24 07:35:00 | Complimentary Technical Snapshots on Aquinox Pharma and Three More Healthcare Stocks

2018-07-13 08:39:12 | Akorn AKRX Looks Good: Stock Adds 7.8% in Session

2018-07-10 09:23:01 | Aquinox Pharmaceuticals AQXP Enters Oversold Territory

2018-07-10 08:11:27 | Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

2018-06-28 08:00:00 | Today’s Research Reports on Stocks to Watch: Aquinox Pharmaceuticals and Summit Therapeutics

2018-06-27 17:22:43 | Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today

2018-06-27 14:48:31 | Failed Trial Pushed Aquinox Down almost 83% This Morning

2018-06-27 14:40:00 | Aquinox Pharma Shares Plunge 85% After Failed Test Results

2018-06-27 10:42:20 | Aquinox to stop development of lead drug; shares plunge

2018-06-27 06:30:00 | Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome

2018-06-11 09:05:00 | Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS

2018-05-16 13:32:21 | Aquinox to Present at 2018 UBS Global Healthcare Conference

2018-05-09 21:00:00 | Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

2018-05-08 09:31:26 | Aquinox: 1Q Earnings Snapshot

2018-05-08 09:05:00 | Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

2018-05-07 12:19:19 | How Do Analysts See Aquinox Pharmaceuticals Inc NASDAQ:AQXP Performing Over The Next Few Years?

2018-05-02 12:54:19 | Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference

2018-04-26 09:05:00 | Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference

2018-03-26 07:30:00 | Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%

2018-03-21 09:00:00 | Aquinox to Present at the 17th Annual Needham Healthcare Conference

2018-03-12 17:08:21 | Aquinox reports 4Q loss

2018-03-12 16:05:00 | Aquinox Pharmaceuticals Announces Year End 2017 Financial Results

2018-03-12 13:00:00 | Aquinox Pharmaceuticals, Inc. to Host Earnings Call

2018-03-12 07:36:52 | Morning News Call - Canada, March 12

2018-03-05 09:15:00 | Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results

2018-02-09 08:30:00 | Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor

2018-02-02 09:03:31 | Comparing Cara Therapeutics’ Financial Performance

2018-02-02 07:36:58 | Cara Therapeutics’ Collaboration Agreements

2018-02-02 06:00:00 | Aquinox to Present at LEERINK Partners 7th Annual Global Healthcare Conference

2018-02-01 16:15:02 | An Insight into Cara Therapeutics’ Drug Pipeline

2018-02-01 14:41:22 | Analysts’ Recommendations for Cara Therapeutics in January 2018

2018-01-26 09:05:00 | Aquinox to Host Analyst and Investor Event in New York City

2017-12-15 09:00:00 | Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

2017-12-07 19:25:50 | Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome IC/BPS

2017-11-22 09:15:00 | Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference

2017-11-08 10:15:27 | Aquinox reports 3Q loss

2017-11-08 09:05:00 | Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results

2017-09-18 16:15:00 | Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference